<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755247</url>
  </required_header>
  <id_info>
    <org_study_id>NI-AC004</org_study_id>
    <nct_id>NCT01755247</nct_id>
  </id_info>
  <brief_title>A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers</brief_title>
  <official_title>A Phase One, Single-Center, Open-Label, Randomized, Parllel Group, 3 Day Study Evaluating the Safety and Cutaneous Toleraility of NVN10000 Topical Gel in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novan, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3 day study to assess safety and tolerability of a new topical gel product, NVN1000
      with and without the application of a commercially available moisturizer in approximately 15
      healthy subjects. The test product will be applied to the forehead of healthy volunteers once
      daily for 3 days. One group of subjects will have a moisturizer applied to the same area 15
      minutes after the test gel was applied and one group of subjects will be treated with the gel
      vehicle which does not contain the active product. The hypothesis is that the application of
      moisturizer will not effect safety or local tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous tolerability</measure>
    <time_frame>3 days</time_frame>
    <description>Tolerability based on a four point scale (0-3) for erythema, scaling ,dryness, pruritus, and burning/stinging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 Days</time_frame>
    <description>Safety assessments include the change from baseline in percent methemoglobin, adverse events, and physical exams, including vital signs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Propionobactium acnes counts</measure>
    <time_frame>3 days</time_frame>
    <description>P. acnes counts will be obtained at Baseline, Day 1, and Day 3. The change in P acnes counts over time by treatment group will be assessed.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily application of topical gel vehicle to forehead for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8% NVN1000 Topical Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8% NVN1000 Topical Gel and moisturizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel Vehicle</intervention_name>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8% NVN1000 Topical Gel</intervention_name>
    <arm_group_label>8% NVN1000 Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8% NVN1000 Topical Gel and moisturizer</intervention_name>
    <arm_group_label>8% NVN1000 Topical Gel and moisturizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male and Females &gt; 18 years of age

          -  High degree of fluorescence of facial skin under Wood's lamp

        Exclusion Criteria:

          -  Acute or chronic skin disorders

          -  Topical or systemic antibiotics within 4 weeks of study enrollment

          -  Use of medication that increases risk of methemoglobinemia or influences P. acnes
             counts

          -  Subjects with medical illnesses, anemia, elevated methemoglobin

          -  Women who are pregnant, nursing or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J Leyden</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGL, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGL, Inc</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

